Gan & Lee Pharmaceuticals.
603087
Classifica tra le azioni
#3014
Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused... Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused on the discovery, development, manufacturing, and marketing of insulin analogues within the Chinese market. Their diverse product portfolio encompasses injectable therapies such as Basalin (an insulin glargine), Prandilin (an insulin lispro), Prandilin 25 (another insulin lispro variant), Raplin (an insulin aspart), Raplin 30 (an insulin aspart 30 formulation), and Similin 30 (an insulin injection). Beyond diabetes treatments, the company also offers various medical devices. Established in 1998, Gan & Lee Pharmaceuticals maintains its corporate headquarters in Beijing, People's Republic of China. The organization underwent a name change in April 2005, transitioning from its former identity as Beijing Gan & Lee Biotechnology Co., Ltd.
Prezzo delle azioni
$10.03
Capitalizzazione di mercato
$5.99B
Variazione (1 giorno)
-3.71%
Variazione (1 anno)
2.30%
Paese
CN
Scambia Gan & Lee Pharmaceuticals. (603087)
Categoria
Healthcare
Rapporto P/S per Gan & Lee Pharmaceuticals. (603087)
Rapporto P/S al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Gan & Lee Pharmaceuticals., il rapporto P/S attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/S per Gan & Lee Pharmaceuticals. da 2013 a 2026
Rapporto P/S alla fine di ogni anno
| Anno | Rapporto P/S | Cambia |
|---|---|---|
| 2025 | 9.98 | 16.64% |
| 2024 | 8.56 | -25.20% |
| 2023 | 11.44 | 7.09% |
| 2022 | 10.68 | -2.29% |
| 2021 | 10.94 | -50.49% |
| 2020 | 22.08 | 74.82% |
| 2019 | 12.63 | -8.28% |
| 2018 | 13.77 | -0.87% |
| 2017 | 13.89 | -25.30% |
| 2016 | 18.60 | -31.05% |
| 2015 | 26.97 | -23.67% |
| 2014 | 35.34 | -20.02% |
| 2013 | 44.18 | 0.00% |
Rapporto P/S per aziende simili o concorrenti
| Azienda | Rapporto P/S | Differenza del rapporto P/S | Il paese |
|---|---|---|---|
| 13.45 | - |
US
|
|
| 2.32 | - |
FR
|
|
| - | - |
JP
|
|
| 2.47 | - |
US
|
|
| - | - |
CH
|
